



National Securities Market Commission  
Markets Directorate General  
C/ Edison núm. 4  
28006 Madrid

Colmenar Viejo (Madrid), April 1, 2019

Pursuant to Article 17 of Regulation (EU) n° 596/2014 on market abuse and Article 226 of the consolidated text of the Spanish Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, we hereby make the following REGULATORY ANNOUNCEMENT:

“Please find attached press release that Pharma Mar, S.A. will distribute to the media today in relation to the acceptance by ASCO (American Society of Clinical Oncology) and selection for oral presentation at its 19th Annual Congress of the abstract titled “Efficacy and safety profile of Lurbinectedin in second-line SCLC patients: results from a phase II single-agent trial””.

**Pharma Mar S.A.**  
**Avda. de los Reyes, 1**  
**P.I. La Mina**  
**28770 Colmenar Viejo**  
**(Madrid) Spain**  
**[www.pharmamar.com](http://www.pharmamar.com)**

## ASCO selects PharmaMar's lurbinectedin monotherapy trial for an oral presentation

- In this presentation, the detailed data from the lurbinectedin monotherapy trial in small cell lung cancer will be presented.
- PharmaMar has already announced that the trial met its primary endpoint, as determined by both the investigator and the IRC (Independent Review Committee) assessments.

Madrid, 1<sup>st</sup> of April, 2019. PharmaMar (PHM:MSE) has been notified by the lead author, Dr. Luis Paz-Ares, MD, PhD, Professor of Medicine at the Hospital Universitario 12 de Octubre in Madrid, Spain, that the abstract titled "*Efficacy and safety profile of Lurbinectedin in second-line SCLC patients: results from a phase II single-agent trial*" has been accepted by ASCO (American Society of Clinical Oncology) and has been selected for an oral presentation at the 19<sup>th</sup> Annual Meeting in Chicago, Illinois. Dr. Paz-Ares will present the data on June 1<sup>st</sup>.

In this oral presentation, the results referring to the phase II study of lurbinectedin, in monotherapy, with the 105 patients who have participated will be made public.

PharmaMar has already announced that the trial met its primary endpoint, as determined by both the investigator and the IRC (Independent Review Committee) assessments.

Dr. Paz-Ares and PharmaMar management will host a conference call after the data presentation. More details will follow in due course.

### Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

### About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy,

France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com).

**About lurbinectedin**

Lurbinectedin (PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

**Media Contact:**

Alfonso Ortín – Communications Director [aortin@pharmamar.com](mailto:aortin@pharmamar.com) Mobile: +34 609493127  
Miguel Martínez-Cava – Digital Communication Manager [mmartinez-cava@pharmamar.com](mailto:mmartinez-cava@pharmamar.com) Mobile: +34 606597464  
Phone: +34 918466000



**Investor Relations:**

Phone: +34 914444500

Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)